Business Overview
Incorporated in 2010, Manipal Health Enterprises Limited is one of India’s largest integrated healthcare providers, operating a nationwide network of multi-specialty hospitals, clinics and diagnostic centres. A part of the Manipal Group, founded by Dr. T. M. A. Pai, the company delivers comprehensive healthcare services spanning primary, secondary, tertiary and quaternary care, with strong expertise in high-acuity specialties including oncology, cardiology, neurosciences, organ transplants, orthopaedics and critical care.
The company’s business model is centred on a hub-and-spoke network, where flagship tertiary care hospitals are supported by clinics and smaller hospitals that facilitate patient referrals, improve specialist utilisation and enhance operational efficiency. Revenue is primarily driven by inpatient services, surgeries, diagnostics, pharmacy sales and outpatient consultations, providing diversified and recurring cash flows. Alongside organic capacity expansion, the company has consistently strengthened its market position through strategic acquisitions and brownfield expansions across key healthcare markets.
Manipal Health operates 49 hospitals with 13,037 licensed beds and 21 clinics across India. The company was supported by a workforce of 24,240 employees, including 11,048 nurses, 6,362 paramedics and 6,830 administrative staff, enabling the delivery of high-quality clinical care.
IPO Synopsis
| Particulars | Details |
|---|---|
| IPO Date | 29th July 2026 to 31st July 2026 |
| Face Value | ₹2 per equity share |
| Price Band | ₹560 to ₹590 per equity share |
| Lot Size | 25 shares and in multiples thereof |
| Issue Size | ₹9,275 crore |
| Fresh Issue | ₹8,000 crore |
| Offer for Sale | ₹1,275 crore |
Objective of the Issue
-
Repayment or Prepayment of Borrowings
Repayment or prepayment, in full or in part, of certain outstanding borrowings and accrued interest amounting to ₹5,552 crore. -
Acquisition of Minority Stake in Sahyadri Hospitals
Acquisition of a minority stake in the company’s step-down subsidiary, Sahyadri Hospitals Private Limited, amounting to ₹574 crore. -
General Corporate Purposes
The remaining proceeds from the fresh issue will be used for general corporate purposes.
Strengths
-
Unmatched Physical Scale with a Pan-India Presence
Manipal Health operates 49 hospitals and has 13,037 licensed beds across 14 states and union territories as of 31st March 2026. It is India’s largest private hospital network by bed capacity and the second-largest by hospital count. It is also the only private hospital chain with a leading presence in three major metropolitan markets—Bengaluru, Kolkata and Pune. A network of this scale would be difficult to replicate organically. -
High-Acuity Clinical Portfolio with Strong Brand Equity
The company derives a majority of its inpatient revenue from high-value specialties including cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics and renal sciences. Its focus on complex tertiary and quaternary care, supported by advanced medical infrastructure and a trusted clinical brand, enables a superior case mix, higher realisations and sustained patient inflows. -
Scalable Expansion Strategy Backed by Acquisitions and Capacity Addition
Manipal Health has consistently expanded through strategic acquisitions, including Columbia Asia, AMRI, Medica Synergie and Sahyadri Hospitals, strengthening its presence across key healthcare markets. The company plans to add 2,400 beds over the next three to four years, while its hub-and-spoke model and brownfield expansion strategy support operating leverage, economies of scale and long-term growth.
Risks
-
High Revenue Concentration in Karnataka
Karnataka contributed 46.40% of the company’s revenue in FY26, compared with 59.98% in FY24 and 66.61% in FY23. Despite the reduction, Karnataka remains the company’s largest single-state exposure. Changes in state-level tariff regulations, licensing requirements or competitive intensity in Bengaluru could adversely affect revenue and profitability. -
High Capital Intensity and Leverage Requirements
Hospital expansion requires substantial investment in land, infrastructure, medical equipment and technology before generating returns. Continuous capacity additions and acquisitions increase capital requirements and financing needs. Any slowdown in occupancy growth, lower-than-expected average revenue per occupied bed or delays in commissioning new hospitals could extend payback periods, pressure cash flows and affect return ratios. -
Premium Valuation Leaves Limited Room for Execution Slippage
At the upper price band of ₹590 per share, the company is valued at approximately ₹77,607 crore against an FY26 profit after tax of ₹916 crore, translating to nearly 85 times trailing earnings. The issue is priced above the disclosed peer average P/E of hospital operators such as Apollo Hospitals, Fortis Healthcare and Max Healthcare. Any delay in occupancy ramp-up or margin improvement at Sahyadri Hospitals could negatively affect the stock at these valuation levels.
Financial Snapshot
| Particulars (₹ crore) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Total Income | 10,520.0 | 8,362.0 | 6,265.0 |
| YoY Growth | 25.8% | 33.5% | – |
| EBITDA | 2,795.0 | 2,247.0 | 1,776.0 |
| EBITDA YoY Growth | 24.4% | 26.5% | – |
| EBITDA Margin | 26.6% | 26.9% | 28.3% |
| Profit After Tax | 916.0 | 1,081.0 | 533.0 |
| PAT YoY Growth | -15.3% | 102.8% | – |
| PAT Margin | 8.7% | 12.9% | 8.5% |
| ROE | 10.9% | 18.4% | 13.2% |
| ROCE | 14.7% | 21.1% | 22.3% |
| ROA | 3.7% | 7.7% | 4.9% |
Conclusion
Manipal Health Enterprises has established itself as one of India’s leading private hospital operators, with a diversified network of 49 hospitals, over 13,000 licensed beds and a strong presence across key metropolitan and Tier-I cities. Its integrated healthcare ecosystem, wide specialty mix, high-end tertiary and quaternary care capabilities and successful acquisition-led expansion strategy provide strong competitive advantages. The company has consistently strengthened its operating metrics, with revenue growing to ₹10,520 crore in FY26 while maintaining healthy EBITDA margins of 26.6%, supported by improving occupancy, higher case complexity and a rising contribution from premium specialties. Long-term industry tailwinds such as rising healthcare expenditure, increasing lifestyle diseases, greater insurance penetration and ageing demographics continue to support sustainable demand for organised hospital chains.
That said, investors should monitor a few key factors. Karnataka continues to account for nearly 46% of revenue, keeping earnings exposed to regional concentration. Hospital expansion remains capital intensive, requiring sustained investments before assets mature, while the IPO is priced at a premium valuation of nearly 85 times FY26 earnings, leaving limited room for execution disappointments. Additionally, return ratios have moderated following aggressive expansion and acquisitions.
Despite these monitorable risks, Manipal Health’s leadership position, strong execution track record, scalable platform and favourable healthcare industry outlook make it well positioned for long-term value creation. We recommend the IPO for long-term subscription.
